• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 32Characteristics of rosiglitazone active-control trials with sulfonylurea in adults with type 2 diabetes

Author, year
Quality
Sample size (N)
Follow-up (weeks)
Age (years) (SD)a
% Femalea
% Whitea
% Hispanica
Other population characteristics
InterventionCombination therapy
Bakris 2006141
Fair
374
32
58.8 (SE 9.8)
31
NR
NR
Rosi: start 4 mg daily

Glyburide: start 5 mg daily
Metformin ≥ 1000 mg daily
Derosa 2006142
Good
95
52
52 (5)
48
NR
NR
All subjects had the metabolic syndrome (ATPIII definition) in addition to type 2 diabetes
Rosi 4 mg daily

Glimepiride 2 mg daily
Metformin 1500 mg daily
Garber 2006143
Fair
318
24
56 (NR)
44
80
NR
Inadequately controlled on metformin at baseline
Rosi 4–8 mg daily and metformin 1,500–2,000 mg daily

Glibenclamide- metformin 5/1,000 mg to 10/2,000 mg daily (combination product)
Yes
Gerstein 2010154
Fair
672
78
Glipizide group:
60.2
34.2
NR
NR
Rosi 4–8 mg daily

Glipizide 10–15mg daily
Tapered off other oral agents over month 1; could add metformin or insulin if needed
Hamann 2008144
Multinational
Fair
573
52
59.3 (9.2)
48
95
NR
Overweight subjects (BMI >=25 kg/m2 having received metformin
Rosiglitazone 4–8 mg daily

Sulfonylurea (glibenclamide 5–15 mg daily or gliclazide 80–320 mg daily)
Added to metformin 2000 mg daily
Hanefeld 2007145
Fair
587
52
Glibenclamide group:
60.1 (3.8)
32
NR
NR
Rosi 4 mg daily

Rosi 8 mg daily

Glibenclamide 2.5–15 mg daily
None
Kahn 2006,147
Viberti 2006, 2002155, 156
ADOPT
Fair
4,351
208 (median)
Glyburide group:
56.4 (10.2)
58
NR
NR
Failed lifestyle therapy, recently diagnosed, not on oral agents previously
Rosi 4–8 mg daily

Glyburide: 2.5–7.5 mg daily

Metformin: 500–2,000 mg daily
None
Pop-Busui 2009149
USA
Fair
27
26
49.5 (10)
23
NR
NR
Treated with diet/exercise or SU alone
Rosiglitazone 8 mg daily

Glyburide 10 mg daily
None
Von Bibra 2008152
Germany
Fair
12
32
59 (12) b
33
NR
NR
Rosiglitazone 8 mg daily

Glimepiride 3 mg daily
Added to metformin monotherapy
Range
Fair 8
Good 1
12 – 4,351
12–208
49.5 – 60.2
23 – 58
Rosi 4 mg – 8 mg
daily

Abbreviations: BMI, body mass index; CI, confidence interval; NR, not reported; rosi, rosiglitazone; SU, sulfonylurea; wk, week(s); yr, year(s).

a

Baseline data are from the comparison group. Data shown are mean (SD) unless otherwise indicated.

b

Because this was a cross-over study, population characteristics were reported for the entire cohort.

Baseline data are from the comparison group. Data shown are mean (SD) unless otherwise indicated.

Because this was a cross-over study, population characteristics were reported for the entire cohort.

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.